Article
Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
The Journal of antimicrobial chemotherapy - 1 Oct 2014
Mesplède Thibault, Osman Nathan, Wares Melissa, Quashie Peter K, Hassounah Said, Anstett Kaitlin, Han Yingshan, Singhroy Diane N, Wainberg Mark A
Abstract excerpt
BACKGROUND: The results of several clinical trials suggest that the integrase inhibitor dolutegravir may be less prone than other drugs to the emergence of HIV drug resistance mutations in treatment-naive patients. We have shown that the R263K mutation commonly emerged during tissue culture selection studies with dolutegravir and conferred low levels of resistance to this drug while simultaneously diminishing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.